Onconetix (ONCO) Net Cash Flow (2021 - 2026)
Onconetix (ONCO) posted quarterly Net Cash Flow of -$1.5 million for Q1 2026, down 268.65% year-over-year from $870574.0 in Q1 2025, and down 142.6% quarter-over-quarter from $3.4 million in Q4 2025.
Onconetix (ONCO) Net Cash Flow (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Net Cash Flow for 6 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 268.65% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at $2.4 million (up 183.84% YoY), while the FY2025 annual figure was $4.8 million, up 225.69% from the prior year.
- Net Cash Flow eased to -$1.5 million in Q1 2026 per ONCO's latest filing, from $3.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $16.7 million in Q1 2022 and bottomed at -$12.0 million in Q2 2023.
- Historically, Net Cash Flow has averaged $928488.5 across 5 years, with a median of -$31548.0 in 2024.
- Annual changes were most pronounced in 2022 — Net Cash Flow soared 6602.01% — and 2023, when it plunged 431.22%.
- Onconetix's Net Cash Flow stood at -$3.4 million in 2022, then soared by 411.92% to $10.6 million in 2023, then plunged by 96.39% to $381279.0 in 2024, then soared by 803.99% to $3.4 million in 2025, then slumped by 142.6% to -$1.5 million in 2026.
- Business Quant data shows ONCO's Net Cash Flow at -$1.5 million in Q1 2026, $3.4 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.25 Mn |
| Jun 30, 2026 | 2.25 Mn |
| Mar 31, 2026 | -1.47 Mn |
| Mar 31, 2026 | -1.47 Mn |
| Dec 31, 2025 | 3.45 Mn |
| Dec 31, 2025 | 3.45 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | -665,722.00 |
| Jun 30, 2025 | -665,722.00 |
| Mar 31, 2025 | 870,574.00 |
| Mar 31, 2025 | 870,574.00 |
| Dec 31, 2024 | 381,279.00 |
| Dec 31, 2024 | 381,279.00 |
| Sep 30, 2024 | -570,248.00 |
| Sep 30, 2024 | -570,248.00 |
| Jun 30, 2024 | -3.56 Mn |
| Jun 30, 2024 | -3.56 Mn |
| Mar 31, 2024 | -31,548.00 |
| Mar 31, 2024 | -31,548.00 |